-+ 0.00%
-+ 0.00%
-+ 0.00%

Idorsia's daridorexant gains FDA breakthrough therapy designation for pediatric insomnia

PUBT·11/04/2026 06:02:02
Idorsia's daridorexant gains FDA breakthrough therapy designation for pediatric insomnia
  • Idorsia received FDA Breakthrough Therapy Designation for daridorexant to treat insomnia in patients aged 10 to under 18.
  • Reported Phase 2 results showed improved total sleep time, with pronounced benefits in patients with neurodevelopmental disorders and favorable tolerability.
  • The full study manuscript is under journal review; the Phase 3 program is expected to begin in the second half of 2027.
  • The designation enables intensive FDA guidance to accelerate development and review in a market with no FDA-approved pediatric insomnia drugs.
  • Daridorexant remains investigational for pediatric use, with no marketing authorization for children or adolescents in any country.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040100PRIMZONEFULLFEED1001301632) on November 04, 2026, and is solely responsible for the information contained therein.